[Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients.
14 Oct, 2021 | 10:17h | UTCEfficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – medRxiv
Commentary: Novel vaccine demonstrates high efficacy for prevention of COVID-19 – News Medical
Related:
Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.
RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.
New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
Commentary on Twitter
Remember Novavax's #COVID vaccine?
Recent data looks really good.
~30K participants enrolled in a prospective clinical trial.
The vaccine appeared to be safe & effective (>90%).
Unclear why approval is taking so long.
Preprint ? https://t.co/MQkJXdgJyR pic.twitter.com/217Erw2stC
— Isaac Bogoch (@BogochIsaac) October 12, 2021